<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychol Med</journal-id><journal-id journal-id-type="iso-abbrev">Psychol Med</journal-id><journal-id journal-id-type="publisher-id">PSM</journal-id><journal-title-group><journal-title>Psychological Medicine</journal-title></journal-title-group><issn pub-type="ppub">0033-2917</issn><issn pub-type="epub">1469-8978</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27048954</article-id><article-id pub-id-type="pmc">4954262</article-id><article-id pub-id-type="doi">10.1017/S0033291716000398</article-id><article-id pub-id-type="pii">S0033291716000398</article-id><article-id pub-id-type="publisher-id">00039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Memantine augmentation in clozapine-refractory schizophrenia: a randomized,
double-blind, placebo-controlled crossover study</article-title><alt-title alt-title-type="left-running">S. R. T. Veerman et al.</alt-title><alt-title alt-title-type="right-running">Memantine augmentation in clozapine-refractory
schizophrenia</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Veerman</surname><given-names>S. R. T.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Schulte</surname><given-names>P. F. J.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>J. D.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>de Haan</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Mental Health Service Organization North Holland
North, Community Mental Health Division</addr-line>, <institution>Flexible Assertive
Community Treatment</institution>, <addr-line>Alkmaar</addr-line>, <country>The
Netherlands</country></aff><aff id="aff2"><label>2</label><addr-line>Mental Health Service Organization North Holland
North, Division for Specialized Treatment</addr-line>, <institution>Treatment Center for
Bipolar Disorders</institution>, <addr-line>Alkmaar</addr-line>, <country>The
Netherlands</country></aff><aff id="aff3"><label>3</label><addr-line>Department of Psychiatry and Behavioral
Sciences</addr-line>, <institution>Northwestern University, Feinberg School of Medicine,
Center for Prevention Implementation Methodology</institution>, <addr-line>Chicago,
IL</addr-line>, <country>USA</country></aff><aff id="aff4"><label>4</label><addr-line>Early Psychosis Department</addr-line>,
<institution>Academic Medical Center, University of Amsterdam, Academic Psychiatric
Center</institution>, <addr-line>Arkin</addr-line>, <addr-line>Amsterdam</addr-line>,
<country>The Netherlands</country></aff><author-notes><corresp id="cor1"><label>*</label>Address for correspondence: <addr-line>S. R. T. Veerman,
M.D.</addr-line>, <addr-line>Mental Health Service Organization North Holland
North</addr-line>, <addr-line>Community Mental Health Division</addr-line>,
<institution>Flexible Assertive Community Treatment</institution>, <addr-line>Oude
Hoeverweg 10</addr-line>, <addr-line>1816 BT Alkmaar</addr-line>, <country>The
Netherlands</country>. (Email: <email>s.veerman@ggz-nhn.nl</email>)</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>06</day><month>4</month><year>2016</year></pub-date><volume>46</volume><issue>9</issue><fpage>1909</fpage><lpage>1921</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>30</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Cambridge University Press 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Cambridge University Press</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits
unrestricted re-use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0033291716000398a.pdf"/><abstract abstract-type="normal"><sec id="sec_a1"><title>Background</title><p>Dysfunction of neuroplasticity due to <italic>N</italic>-methyl-<sc>d</sc>-aspartate
(NMDA) receptor hypofunction may be a causal factor for memory and executive
dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal
cortex may also explain negative and positive symptoms. Clozapine augmentation with
memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and
showed substantial beneficial effects on several symptom domains in a small
proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine
for memory and executive function, and negative and positive symptoms in
schizophrenia.</p></sec><sec id="sec_a2" sec-type="methods"><title>Method</title><p>Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12
weeks of double-blind adjunctive treatment with memantine (<italic>n</italic> = 26) or
placebo (<italic>n</italic> = 26). Crossover occurred after a 2-week placebo wash-out
period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks
to 26 weeks treatment on memory and executive function using the Cambridge
Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale
(PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were
assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale.</p></sec><sec id="sec_a3" sec-type="results"><title>Results</title><p>When compared with placebo, memantine improved a composite memory score comprising
verbal recognition memory and paired associates learning task scores on the CANTAB
(effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side
effects were mild and transient.</p></sec><sec id="sec_a4" sec-type="conclusion"><title>Conclusions</title><p>In patients with clozapine-treated refractory schizophrenia, memantine addition
significantly improved verbal and visual memory and negative symptoms without serious
adverse effects. These results justify further investigations on long-term memantine
augmentation to clozapine in treatment-resistant schizophrenia.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Antipsychotics</kwd><kwd>cognitive functioning</kwd><kwd>memantine</kwd><kwd>randomized controlled trials</kwd><kwd>therapy-resistant schizophrenia</kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><ref-count count="64"/><page-count count="13"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Although clozapine is efficacious for treatment-resistant schizophrenia patients, as many
as 70% of patients show only a partial response (Hasan <italic>et al.</italic>
<xref rid="ref20" ref-type="bibr">2012</xref>). Polypharmacy is frequently used; however,
evidence concerning additional pharmacological treatment of refractory schizophrenia is
limited (Muscatello <italic>et al.</italic>
<xref rid="ref39" ref-type="bibr">2014</xref>; Veerman <italic>et al.</italic>
<xref rid="ref57" ref-type="bibr">2014<italic>a</italic></xref>,&#x000a0;<xref rid="ref58" ref-type="bibr">
<italic>b</italic>
</xref>). Novel avenues of research are needed to bring about improved drug treatment of
schizophrenia.</p><p>On the basis of the glutamate hypothesis, with hypofunction of the glutamate
<italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor as an underlying mechanism
for schizophrenia (Stone <italic>et al.</italic>
<xref rid="ref52" ref-type="bibr">2007</xref>; Kantrowitz &#x00026; Javitt, <xref rid="ref26" ref-type="bibr">2010</xref>), glutamate modulators can be seen as promising
antipsychotic agents (Veerman <italic>et al.</italic>
<xref rid="ref59" ref-type="bibr">2014</xref><italic>c</italic>). The glutamate hypothesis
of schizophrenia stipulates that hypofunction of the NMDA receptor is responsible for
excitotoxic neurodegeneration, dysfunction of neuroplasticity and dysregulation of
downstream neurons in response to glutamate release, resulting in cognitive impairment and
negative symptoms (Javitt &#x00026; Zukin, <xref rid="ref24" ref-type="bibr">1991</xref>;
Bressan &#x00026; Pilowsky, <xref rid="ref6" ref-type="bibr">2000</xref>; Howes &#x00026;
Kapur, <xref rid="ref22" ref-type="bibr">2009</xref>; Orellana &#x00026; Slachevsky, <xref rid="ref42" ref-type="bibr">2013</xref>). Positive symptoms may develop through
disinhibition of prefrontal cortical &#x003b3;-amino butyric acid (GABA) interneurons, which are
responsible for recurrent inhibition of pyramidal neurons (Homayoun &#x00026; Moghaddam,
<xref rid="ref21" ref-type="bibr">2007</xref>).</p><p>Memantine acts as a low-affinity type, uncompetitive, non-selective and voltage-dependent
NMDA receptor antagonist (Parsons &#x00026; Gilling, <xref rid="ref44" ref-type="bibr">2007</xref>). Memantine is licensed for treatment of moderate-to-severe Alzheimer's disease
(AD) (Areosa <italic>et al.</italic>
<xref rid="ref3" ref-type="bibr">2005</xref>). Efficacy in patients with moderate-to-severe
AD was demonstrated in a meta-analysis of six randomized placebo-controlled trials showing
modest beneficial effects on global status and cognition after treatment with memantine
(Winblad <italic>et al.</italic>
<xref rid="ref62" ref-type="bibr">2007</xref>). Memantine has a favorable safety and
tolerability profile (Farlow <italic>et al.</italic>
<xref rid="ref12" ref-type="bibr">2008</xref>).</p><p>Favorable effects of memantine addition to non-clozapine antipsychotics described in case
reports and open studies were replicated in only one of three placebo-controlled trials of
memantine in combination with non-clozapine antipsychotics (Lieberman <italic>et al.</italic>
<xref rid="ref33" ref-type="bibr">2009</xref>; Lee <italic>et al.</italic>
<xref rid="ref29" ref-type="bibr">2012</xref>; Rezaei <italic>et al.</italic>
<xref rid="ref47" ref-type="bibr">2013</xref>). However, memantine is thought to be more
promising as an adjunctive therapy to clozapine than to non-clozapine antipsychotics. One
small 12-week randomized, placebo-controlled trial (<italic>n</italic>&#x000a0;=&#x000a0;21) demonstrated
efficacy of memantine augmentation in patients with partial remission of negative symptoms
of schizophrenia on clozapine treatment with large effect sizes (ESs) for overall symptoms
(ES&#x000a0;=&#x000a0;2.75), positive symptoms (ES&#x000a0;=&#x000a0;1.38), negative symptoms (ES&#x000a0;=&#x000a0;3.33) and global
cognitive functioning (ES&#x000a0;=&#x000a0;&#x02212;1.32) (de Lucena <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2009</xref>).</p><p>The favorable effects of memantine augmentation to clozapine may be related to their
conjunct action on NMDA receptors. This particular combination modulates glutamatergic
neurotransmission at multiple levels (Veerman <italic>et al.</italic>
<xref rid="ref59" ref-type="bibr">2014<italic>c</italic></xref>): clozapine induces both
up-regulation of <italic>&#x003b1;</italic>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors and NMDA receptors (Yeun <italic>et al.</italic>
<xref rid="ref64" ref-type="bibr">2010</xref>; Tanahashi <italic>et al.</italic>
<xref rid="ref54" ref-type="bibr">2012</xref>), and memantine may enhance further
up-regulation of NMDA receptors causing activation in the presence of a strong stimulus
(Joshi <italic>et al.</italic>
<xref rid="ref25" ref-type="bibr">2007</xref>). NMDA receptors are highly expressed in the
hippocampus (Bliss &#x00026; Collingridge, <xref rid="ref5" ref-type="bibr">1993</xref>).
Improvement of hippocampal dysfunction and functional connectivity between brain circuits,
involving the prefrontal cortex (PFC) through NMDA-receptor mediated neuroplasticity,
explains why combination therapy of clozapine and memantine possibly targets two specific
cognitive domains: impaired memory and executive function.</p><p>Inspired by the unique functional psychopharmacological characteristics of the
memantine&#x02013;clozapine combination and the substantial positive findings of the first
proof-of-concept study, we conducted a second, larger and more elaborate trial studying
effects of adjunctive memantine therapy on memory, executive function and symptom severity
in clozapine-treated patients suffering from refractory schizophrenia.</p></sec><sec sec-type="methods" id="sec2"><title>Method</title><sec id="sec2-1"><title>Study design</title><p>The study was approved by the Central Committee on Research Involving Human Subjects and
the Medical Research Ethics Committee (MREC) of Alkmaar Medical Center and was conducted
in accordance with the Declaration of Helsinki (World Medical Association, <xref rid="ref63" ref-type="bibr">2013</xref>). The study was a 26-week single-center,
double-blind trial that was randomized and placebo controlled. The trial consisted of two
crossover, 12-week treatment phases and a placebo wash-out period of 2 weeks in the 13th
and 14th week to avoid carryover effects (<xref ref-type="fig" rid="fig01">Fig. 1</xref>).
Clozapine dosage and use of concomitant medications were at the discretion of the treating
psychiatrist and remained as much unaltered as possible throughout the study. Subjects
were randomly assigned to receive an identical number of either memantine or placebo
tablets. During the memantine phase a dosage of 10&#x000a0;mg taken once daily was built up after
1 week to 20&#x000a0;mg taken once daily during 11 weeks as add-on therapy to ongoing clozapine
treatment. The dose of 20&#x000a0;mg/day was similar to the dosage used in all four randomized
placebo-controlled trials in patients with schizophrenia (de Lucena <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2009</xref>; Lieberman <italic>et al.</italic>
<xref rid="ref33" ref-type="bibr">2009</xref>; Lee <italic>et al.</italic>
<xref rid="ref29" ref-type="bibr">2012</xref>; Rezaei <italic>et al.</italic>
<xref rid="ref47" ref-type="bibr">2013</xref>). <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Patient disposition in a double-blind, randomized, placebo-controlled trial of
memantine as adjunctive treatment to clozapine in refractory schizophrenia. SAE,
Serious adverse event; AE, adverse event.</p></caption><graphic xlink:href="S0033291716000398_fig1"/></fig></p><p>Randomization to starting with either memantine or placebo was designated on a 1:1 basis
in blocks of four. The allocation sequence was produced independently by the pharmacist of
the VU Medical Center in Amsterdam. The code was concealed for patients, care providers,
raters and investigators until all subjects had completed the trial and data had been
entered into a computer data file.</p></sec><sec id="sec2-2"><title>Study population, inclusion and exclusion criteria</title><p>The study was performed from August 2013 until August 2014, at 12 Flexible Assertive
Community Treatment (FACT) facilities of the Mental Health Service Organization North
Holland North (Netherlands) (van Veldhuizen, <xref rid="ref55" ref-type="bibr">2007</xref>). The original eligibility criterion of &#x02018;out-patients&#x02019; was broadened to
patients living either independently or in a sheltered home and patients admitted to open
long-stay wards, receiving care from an out-patient facility. This was reported to the
MREC of Alkmaar Medical Center. Eligible subjects were between the ages of 18 and 60
years, met Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)
criteria for schizophrenia on the Mini International Neuropsychiatric Interview Plus
(MINI-Plus) (Overbeek <italic>et al.</italic>
<xref rid="ref43" ref-type="bibr">1999</xref>), and failed to achieve remission criteria
proposed by Andreasen <italic>et al.</italic> (<xref rid="ref2" ref-type="bibr">2005</xref>), defined as simultaneous ratings of mild or less (&#x02a7d;3 points) on eight of the
following Positive and Negative Syndrome Scale (PANSS) items: P1 delusions, G9 unusual
thought content, P3 hallucinatory behavior, P2 conceptual disorganization, G5 mannerisms
and posturing, N1 blunted affect, N4 passive or apathetic social withdrawal, N6 lack of
spontaneity and flow of conversation. At inclusion, duration of clozapine therapy was at
least 6 months with a minimum of 12 weeks with a clozapine plasma level above 350&#x000a0;ng/ml or
intolerability to achieve this threshold (Schulte, <xref rid="ref48" ref-type="bibr">2003</xref>). Patients with a recent deterioration needing treatment in an acute
treatment ward were not included. Other exclusion criteria included pregnancy, lactating
women, and female subjects without adequate contraception, known hypersensitivity to
memantine, co-medication with glutamate modulators, lactose intolerance, uncontrolled
epilepsy, myocardial infarction, uncontrolled hypertension, renal insufficiency, liver
failure or AD (Wesemann <italic>et al.</italic>
<xref rid="ref61" ref-type="bibr">1983</xref>). The sample size was calculated at 52,
based on an ES of 0.55 (<italic>&#x003b1;</italic>&#x000a0;=&#x000a0;0.05, power&#x000a0;=&#x000a0;0.80) and accounting for an
estimated discontinuation rate of 20%. After complete description of the study to the
subjects, written informed consent was obtained by the principal investigator. Care
providers distributed study medication and monitored compliance on a daily basis in
patients in sheltered homes and open long-stay wards and on a weekly basis in
out-patients.</p></sec><sec id="sec2-3"><title>Clinical assessments</title><p>We used the Cambridge Neuropsychological Test Automated Battery (CANTAB), a computerized,
non-linguistic cognitive testing battery (Levaux <italic>et al.</italic>
<xref rid="ref32" ref-type="bibr">2007</xref>). Test selection was based on six cognitive
domains, recommended by the Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS): reaction time and psychomotor speed, sustained visual attention,
verbal memory, visuospatial memory, learning and association ability, working visuospatial
memory and strategy use, spatial planning and motor control and emotion recognition
(Nuechterlein <italic>et al.</italic>
<xref rid="ref41" ref-type="bibr">2008</xref>; Barnett <italic>et al.</italic>
<xref rid="ref4" ref-type="bibr">2010</xref>). One cognitive domain of the MATRICS
Consenus Cognitive Battery (MCCB) was not assessed, because Intra/Extra-Dimensional
Set-Shifting (IED) for reasoning and problem solving was too difficult for our patient
population with severe cognitive disturbances.</p><p>Two cognitive domains were selected as primary outcomes: memory and executive function
(see Table 2). Memory was assessed by computing a composite score of the sum of the CANTAB
scores of four tasks: verbal recognition memory (VRM) free recall and VRM recognition, and
paired associates learning (PAL) total errors and PAL first trial memory score. To reduce
practice effects a parallel form of the VRM task, equivalent in difficulty, was used for
the second and fourth measurement. Executive function was assessed by computing a
composite of three CANTAB task scores: One Touch Stockings of Cambridge (OTS) problems
solved on first choice, and spatial working memory (SWM) strategy and SWM between errors.</p><p>The PANSS was used to assess severity of positive, negative and total symptoms of
schizophrenia (Kay <italic>et al.</italic>
<xref rid="ref27" ref-type="bibr">1987</xref>). We assessed the effect of memantine on two
subdomains of negative symptoms: (1) expressive deficits [flat affect (N1), poor rapport
(N3), lack of spontaneity and flow of conversation (N6), mannerisms and posturing (G5),
motor retardation (G7) and avolition (G13)]; and (2) social amotivation [emotional
withdrawal (N2), passive/apathetic social withdrawal (N4) and active social avoidance
(G16)] (Liemburg <italic>et al.</italic>
<xref rid="ref34" ref-type="bibr">2013</xref>; Millan <italic>et al.</italic>
<xref rid="ref37" ref-type="bibr">2014</xref>). Global severity of psychopathology was
determined by using the Clinical Global Impression Severity Scale (CGI-S) (Guy, <xref rid="ref18" ref-type="bibr">1976</xref>).</p><p>Careful clinical procedures were performed to assess safety and tolerability of memantine
add-on therapy to clozapine. Physical examination included measurements of waist
circumference and blood pressure. Regular controls of white blood cell count and
differentiation were combined with measurements of liver and renal function, blood
glucose, lipids and plasma clozapine level (12&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;h after ingestion). The occurrence
and intensity of side effects were assessed by self-rating on the Liverpool University
Neuroleptic Side-Effect Rating Scale (LUNSERS) (Day <italic>et al.</italic>
<xref rid="ref8" ref-type="bibr">1995</xref>) augmented with rating of Likert scales for
possible side effects of memantine (thrombosis, dyspnoea, and mycosis).</p><p>All outcomes were rated before treatment initiation, after 12 weeks, after 14 weeks, and
after 26 weeks. Two raters were trained in diagnostic interviewing and all clinical
assessments. Inter-rater exact and adjacent agreement (within one scale point) was 96% for
the PANSS, based on seven assessments (two live patient interviews and five videotaped
patient interviews).</p><p>Adverse events (AEs) were defined as any undesirable experience occurring to a subject
during the study, whether or not they were considered to be related to memantine
ingestion. All AEs, reported by either the subject or treatment staff, were recorded.
Admission to a psychiatric hospital was no reason to break the code or for withdrawal from
the study. A medical emergency was the only reason to break the code and withdraw the
subject from the study.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>To determine the effects of memantine on the hypothesized cognitive functions,
schizophrenia symptoms, safety measures, and side effects, the two phases (memantine or
placebo) of the crossover trial were compared using a linear mixed-effects model conducted
in SPSS Statistics version 22.0.0 (SPSS Inc., <xref rid="ref51" ref-type="bibr">2014</xref>). This analytic approach can estimate random and fixed effects simultaneously
(Putt &#x00026; Chinchilli, <xref rid="ref46" ref-type="bibr">1999</xref>). A natural log
transformation was applied to cognitive function scores assessed via the CANTAB, which are
non-normally distributed, so that estimates from the linear mixed-effects models would be
trustworthy.</p><p>We conducted the analyses using an intention-to-treat (ITT) analytic approach and a
per-protocol analytic approach, which included only protocol completers. Protocol
completion was defined as having completed both treatment phases without a serious
protocol violation in the memantine phase. There was no significant difference in study
completion rate by random group assignment (group 1&#x000a0;=&#x000a0;23/26, group 2&#x000a0;=&#x000a0;21/26;
&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;1.209, <italic>p</italic>&#x000a0;=&#x000a0;0.47). We also tested a number
of covariates in the model, which are potentially related to the dependent variables.
Covariates included patient age and gender, years of education, age of onset, duration of
psychosis and duration of untreated psychosis. We followed the backwards trimming method
described by Singer &#x00026; Willett (<xref rid="ref50" ref-type="bibr">2003</xref>) to
construct our models: as covariates were entered into the model, one at a time, those that
were significantly related to one of the model's parameters were retained. Only the
patient's years of education variable was related to the slope paramater; thus, this
variable was retained in the final model and the others were discarded.</p><p>We first tested a model with random intercepts. However, the models failed to converge or
produced errors in the Hessian matrix, so the intercept parameter was fixed to ensure
trustworthy parameter estimates. The slope parameter was treated as a fixed effect after
it was found that models with random slopes resulted in worse model fit. This indicates
that models with fixed intercepts and slopes (i.e. constraining these parameters to be
equal across participants) do not significantly differ from models in which these
parameters are individually estimated. All tests of significance were two-tailed, and
<italic>&#x003b1;</italic> was set to 0.05. Standardized ESs (Cohen's <italic>d</italic>) were
calculated (Cohen, <xref rid="ref7" ref-type="bibr">1988</xref>). We performed a
<italic>post-hoc</italic> analysis to assess whether memantine had a more pronounced
effect on expressive deficits or social amotivation. To evaluate possible differences
between in-patients admitted to long-stay wards and other included patients we performed a
<italic>post-hoc</italic> analysis of demographic variables and baseline characteristics
and also conducted a <italic>post-hoc</italic> analysis of out-patients, excluding
patients admitted to long-stay wards.</p></sec><sec id="sec2-5"><title>Reliability of analyses</title><p>To include the full, randomized sample in the analyses, restricted maximum likelihood
estimation was used, which has been shown to provide unbiased estimates when data are
missing at random or missing completely at random (MCAR) (Little &#x00026; Rubin, <xref rid="ref35" ref-type="bibr">2002</xref>). There was some degree of missing data in our
sample (see <xref ref-type="table" rid="tab02">Tables 2</xref> and <xref ref-type="table" rid="tab03">3</xref> and online Supplementary Tables S1 and S2 for valid
<italic>n</italic>'s), but the data were determined to be MCAR (39)
(&#x003c7;<sup>2</sup><sub>737</sub>&#x000a0;=&#x000a0;144.40, <italic>p</italic>&#x000a0;=&#x000a0;1.00), so the missing data did
not introduce bias into the analyses.</p><p>Two steps were taken in the analytic strategy to address unique sources of potential bias
in the crossover design: (1) a period effect parameter and a period&#x000a0;&#x000d7;&#x000a0;treatment
interaction were tested to determine whether the order in which memantine was received was
related to the outcome and whether there was a larger effect in one of the phases of the
trial<xref ref-type="fn" rid="fn2">
<sup>2</sup>
</xref>; and (2) carryover effects were controlled for in all analyses.</p><p>Other possible confounders were analysed, such as change in clozapine dosage,
concomittant medication, substance use, and use of psychotherapy during the study. The
element of expectation of the placebo response was tested by examining whether pretrial
expectations of positive benefits of memantine moderated the effect on the outcomes of
active drug and placebo. Further, we analysed the degree of successful blinding by
examining the degree of accurate appraisal of receipt of memantine from the perspective of
the patient and the rater.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Baseline characteristics</title><p><xref ref-type="fig" rid="fig01">Fig. 1</xref> presents participant screening and
enrolment flow data. A total of 134 patients were screened, of whom 116 patients met
inclusion criteria; 64 eligible patients refused participation. The remaining 52 patients
gave informed consent and were enrolled. <xref ref-type="table" rid="tab01">Table 1</xref>
presents demographic and clinical characteristics of the study population. Omnibus tests
revealed that the two groups did not differ on any parameter except for significantly
higher expectations for improvement in daily activities and living conditions in the group
first assigned to placebo, compared with the group first assigned to memantine. A
<italic>post-hoc</italic> analysis showed no significant differences between the six
in-patients and the 46 out-patients on any of the demographic variables or baseline
characteristics. <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient demographics and baseline characteristics</p></caption><alternatives><graphic xlink:href="S0033291716000398_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="2" align="left" rowspan="1">Omnibus test</th></tr><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Mean <sc>(s.d.)</sc></th><th align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup>/<italic>F</italic></th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.923</td><td rowspan="1" colspan="1">0.52</td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">13 (25)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">39 (75)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">42.35 (9.55)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;3.165</td><td rowspan="1" colspan="1">0.08</td></tr><tr><td rowspan="1" colspan="1">Years of education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12.23 (1.79)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;0.596</td><td rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">Education level</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.202</td><td rowspan="1" colspan="1">0.90</td></tr><tr><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">28 (53.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Middle</td><td rowspan="1" colspan="1">17 (32.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">28 (13.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Living conditions</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Independently</td><td rowspan="1" colspan="1">30 (57.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sheltered home</td><td rowspan="1" colspan="1">16 (30.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Long-stay department</td><td rowspan="1" colspan="1">6 (11.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age of onset, years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">19.46 (4.68)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;2.848</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">Duration of untreated psychosis, months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">35.04 (39.80)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;0.818</td><td rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">Duration of illness, years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">22.88 (7.99)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;1.24</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">Alcohol use</td><td rowspan="1" colspan="1">18 (34.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.000</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Cannabis use</td><td rowspan="1" colspan="1">9 (17.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;1.209</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Cocaine use</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;1.020</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Amphetamine use</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;1.020</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Clozapine daily dose, mg</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">350.00 (182.84)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;0.171</td><td rowspan="1" colspan="1">0.68</td></tr><tr><td rowspan="1" colspan="1">Clozapine monotherapy (single antipsychotic)</td><td rowspan="1" colspan="1">36 (69.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;2.342</td><td rowspan="1" colspan="1">0.22</td></tr><tr><td rowspan="1" colspan="1">Combination clozapine&#x000a0;+&#x000a0;second antipsychotic<xref ref-type="table-fn" rid="tfn1_1">
<sup>a</sup>
</xref></td><td rowspan="1" colspan="1">16 (30.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;3.250</td><td rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="1" colspan="1">Combination clozapine&#x000a0;+&#x000a0;antidepressant</td><td rowspan="1" colspan="1">30 (57.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.315</td><td rowspan="1" colspan="1">0.78</td></tr><tr><td rowspan="1" colspan="1">Combination clozapine&#x000a0;+&#x000a0;mood stabilizer<xref ref-type="table-fn" rid="tfn1_2">
<sup>b</sup>
</xref></td><td rowspan="1" colspan="1">6 (11.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;3.014</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">Combination clozapine&#x000a0;+&#x000a0;benzodiazepine</td><td rowspan="1" colspan="1">18 (34.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.000</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Psychotherapy during past 6 months</td><td rowspan="1" colspan="1">4 (7.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;0.000</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Family members or partners involved in the study</td><td rowspan="1" colspan="1">26 (50.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>1</sub>&#x000a0;=&#x000a0;4.600</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Expected improvement due to memantine</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3.50 (0.918)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;0.818</td><td rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">2 (3.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very little</td><td rowspan="1" colspan="1">3 (5.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Little</td><td rowspan="1" colspan="1">20 (38.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Much</td><td rowspan="1" colspan="1">21 (40.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very much</td><td rowspan="1" colspan="1">6 (11.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Expected improvement in personal hygiene</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.19 (1.37)</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;4.671</td><td rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1">Expected improvement in personal relationships</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.75 (1.17)</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;3.444</td><td rowspan="1" colspan="1">0.49</td></tr><tr><td rowspan="1" colspan="1">Expected improvement in daily activities</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3.00 (1.21)</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;12.600</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">Expected improvement in living conditions</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.35 (1.27)</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;11.200</td><td rowspan="1" colspan="1">0.04</td></tr><tr><td rowspan="1" colspan="1">Expected improvement in finances</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.83 (1.18)</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;3.586</td><td rowspan="1" colspan="1">0.17</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p><sc>s.d.</sc>, Standard deviation.</p></fn><fn id="tfn1_1"><label>a</label><p>Eleven patients received aripiprazole, two patients received quetiapine, one
patient received olanzapine and one patient received zuclopenthixol acetate.</p></fn><fn id="tfn1_2"><label>b</label><p>Four patients received valproate and two patients received lithium.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-2"><title>Clinical efficacy results</title><p>Analysis of effects using an ITT approach, presented in <xref ref-type="table" rid="tab02">Table 2</xref>, indicated that all effects were in the direction of desired
effect. The following primary outcome variables significantly improved during the
memantine phase in comparison with the placebo phase: memory composite
(<italic>F</italic><sub>4,655</sub>, ES&#x000a0;=&#x000a0;0.30, <italic>p</italic>&#x000a0;=&#x000a0;0.032); PANSS
negative symptoms (<italic>F</italic><sub>1,84</sub>&#x000a0;=&#x000a0;4.170, ES&#x000a0;=&#x000a0;0.29,
<italic>p</italic>&#x000a0;=&#x000a0;0.043). Other primary outcomes did not significantly improve after
addition of memantine compared with placebo: executive function composite
(<italic>F</italic><sub>1,84</sub>&#x000a0;=&#x000a0;4.655, ES&#x000a0;=&#x000a0;0.12, <italic>p</italic>&#x000a0;=&#x000a0;0.395);
PANSS positive symptoms (<italic>F</italic><sub>1,84</sub>&#x000a0;=&#x000a0;1.008, ES&#x000a0;=&#x000a0;0.15,
<italic>p</italic>&#x000a0;=&#x000a0;0.299); PANSS total symptoms
(<italic>F</italic><sub>1,84</sub>&#x000a0;=&#x000a0;1.869, ES&#x000a0;=&#x000a0;0.19, <italic>p</italic>&#x000a0;=&#x000a0;0.174); CGI
(<italic>F</italic><sub>1,84</sub>&#x000a0;=&#x000a0;0.591, ES&#x000a0;=&#x000a0;0.11, <italic>p</italic>&#x000a0;=&#x000a0;0.443). A
<italic>post-hoc</italic> analysis on PANSS negative symptoms showed that memantine had
a more pronounced effect on the expressive deficits subscale score (ES&#x000a0;=&#x000a0;0.17) compared
with the social amotivation subscale score (ES&#x000a0;=&#x000a0;0.01). <xref ref-type="table" rid="tab02">Table 2</xref> contains the results of analyses on the individual CANTAB tasks
comprising the two composite scores for reference only. No specific hypotheses were tested
concerning the individual CANTAB tasks. <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Intention-to-treat analysis of primary treatment effects<xref ref-type="table-fn" rid="tfn2_2">
<sup>a</sup>
</xref></p></caption><alternatives><graphic xlink:href="S0033291716000398_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="4" align="left" rowspan="1">Intention to treat
(<italic>n</italic>&#x000a0;=&#x000a0;52)</th></tr><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">CO</th><th align="left" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" rowspan="1" colspan="1"><italic>F</italic> test</th><th align="left" rowspan="1" colspan="1">ES</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cognitive domains and CANTAB tasks</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Verbal memory</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">VRM free recall &#x02013; total correct (phase 1)</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">11.818</td><td rowspan="1" colspan="1">0.48*</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">VRM recognition &#x02013; total correct</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">1.421</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">0.235</td></tr><tr><td rowspan="1" colspan="1">Associative learning and short-term visuospatial
memory</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PAL total errors (adjusted)</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">1.219</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1">0.271</td></tr><tr><td rowspan="1" colspan="1">PAL first trial memory score</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">5.778</td><td rowspan="1" colspan="1">0.34*</td><td rowspan="1" colspan="1">0.017</td></tr><tr><td rowspan="1" colspan="1">Memory composite</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">4.655</td><td rowspan="1" colspan="1">0.30*</td><td rowspan="1" colspan="1">0.032</td></tr><tr><td rowspan="1" colspan="1">Working visuospatial memory and strategy use</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SWM strategy</td><td rowspan="1" colspan="1">0.32</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">0.159</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.690</td></tr><tr><td rowspan="1" colspan="1">SWM between errors</td><td rowspan="1" colspan="1">0.47</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">1.522</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1">0.219</td></tr><tr><td rowspan="1" colspan="1">Visual planning, reasoning and impulsivity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">OTS problems solved on first choice</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">0.048</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.827</td></tr><tr><td rowspan="1" colspan="1">Executive function composite</td><td rowspan="1" colspan="1">0.47</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">0.726</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.395</td></tr><tr><td rowspan="1" colspan="1">CGI-S</td><td rowspan="1" colspan="1">0.32</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">0.591</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.443</td></tr><tr><td rowspan="1" colspan="1">PANSS-P</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">1.088</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">0.299</td></tr><tr><td rowspan="1" colspan="1">PANSS-N</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">4.170</td><td rowspan="1" colspan="1">0.29*</td><td rowspan="1" colspan="1">0.043</td></tr><tr><td rowspan="1" colspan="1">PANSS total</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">1.869</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">0.174</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>CO, Carryover effect (<italic>p</italic> value of paired <italic>t</italic>
test); ES, effect size (Cohen's <italic>d</italic>); CANTAB, Cambridge
Neuropsychological Test Automated Battery; VRM, verbal recognition
memory-immediate (free recall) and verbal recognition memory-delayed
(recognition); PAL, paired associates learning; SWM, spatial working memory; OTS,
One Touch Stockings of Cambridge; CGI-S, Clinical Global Impression Severity
Scale; PANSS, Positive and Negative Syndrome Scale; PANSS-P, PANSS positive
subscale; PANSS-N, PANSS negative subscale; PANSS total, PANSS total symptom
score.</p></fn><fn id="tfn2_2"><label>a</label><p>All effects were in the direction of the desired effect.</p></fn><fn><p>* Significant beneficial effect.</p></fn></table-wrap-foot></table-wrap></p><p>This pattern of significant results in the ITT approach was consistent with the
per-protocol analyses: memory composite (<italic>F</italic><sub>4,150</sub>, ES&#x000a0;=&#x000a0;0.31,
<italic>p</italic>&#x000a0;=&#x000a0;0.043); and PANSS negative symptoms
(<italic>F</italic><sub>1,72</sub>&#x000a0;=&#x000a0;3.514, ES&#x000a0;=&#x000a0;0.21, <italic>p</italic>&#x000a0;=&#x000a0;0.043). <xref ref-type="table" rid="tab02">Tables 2</xref> and <xref ref-type="table" rid="tab03">3</xref> and online Supplementary Tables S1 and S2 summarize results and statistics of
primary outcomes, side effects and safety measures. <table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Side effects and safety measures</p></caption><alternatives><graphic xlink:href="S0033291716000398_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="2" align="left" rowspan="1">Omnibus test</th></tr><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Baseline (<italic>n</italic>&#x000a0;=&#x000a0;52)</th><th align="left" rowspan="1" colspan="1">Memantine 1 (<italic>n</italic>&#x000a0;=&#x000a0;25)</th><th align="left" rowspan="1" colspan="1">Placebo 1 (<italic>n</italic>&#x000a0;=&#x000a0;24)</th><th align="left" rowspan="1" colspan="1">After wash-out
(<italic>n</italic>&#x000a0;=&#x000a0;44)</th><th align="left" rowspan="1" colspan="1">Memantine 2 (<italic>n</italic>&#x000a0;=&#x000a0;21)</th><th align="left" rowspan="1" colspan="1">Placebo 2 (<italic>n</italic>&#x000a0;=&#x000a0;24)</th><th align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup>/<italic>F</italic></th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Memantine-related AE mycosis, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>4</sub>&#x000a0;=&#x000a0;5.750</td><td rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">46 (67.3)</td><td rowspan="1" colspan="1">23 (92)</td><td rowspan="1" colspan="1">20 (83.3)</td><td rowspan="1" colspan="1">35 (81.4)</td><td rowspan="1" colspan="1">12 (57.1)</td><td rowspan="1" colspan="1">22 (88.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very little</td><td rowspan="1" colspan="1">2 (3.8)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (12.5)</td><td rowspan="1" colspan="1">3 (7.0)</td><td rowspan="1" colspan="1">6 (28.6)</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Little</td><td rowspan="1" colspan="1">4 (7.7)</td><td rowspan="1" colspan="1">2 (7.7)</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">4 (9.3)</td><td rowspan="1" colspan="1">2 (9.5)</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Much</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (2.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very much</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (4.8)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Memantine-related AE dyspnea, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup><sub>5</sub>&#x000a0;=&#x000a0;5.329</td><td rowspan="1" colspan="1">0.26</td></tr><tr><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">26 (50.0)</td><td rowspan="1" colspan="1">9 (36.0)</td><td rowspan="1" colspan="1">15 (62.5)</td><td rowspan="1" colspan="1">19 (43.2)</td><td rowspan="1" colspan="1">11 (52.4)</td><td rowspan="1" colspan="1">9 (37.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very little</td><td rowspan="1" colspan="1">6 (11.5)</td><td rowspan="1" colspan="1">10 (16.0)</td><td rowspan="1" colspan="1">5 (20.8)</td><td rowspan="1" colspan="1">8 (18.2)</td><td rowspan="1" colspan="1">5 (23.8)</td><td rowspan="1" colspan="1">4 (16.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Little</td><td rowspan="1" colspan="1">13 (25.0)</td><td rowspan="1" colspan="1">4 (40.0)</td><td rowspan="1" colspan="1">3 (12.5)</td><td rowspan="1" colspan="1">14 (31.8)</td><td rowspan="1" colspan="1">4 (19.0)</td><td rowspan="1" colspan="1">8 (33.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Much</td><td rowspan="1" colspan="1">6 (11.5)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (12.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Very much</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1">2 (8.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">2 (4.5)</td><td rowspan="1" colspan="1">1 (4.8)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean LUNSERS scores (<sc>s.d</sc>.)<sup>a</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Extrapyramidal symptoms</td><td rowspan="1" colspan="1">13.37 (4.06)</td><td rowspan="1" colspan="1">13.08 (4.18)</td><td rowspan="1" colspan="1">13.33 (5.31)</td><td rowspan="1" colspan="1">12.34 (3.94)</td><td rowspan="1" colspan="1">13.00 (4.30)</td><td rowspan="1" colspan="1">12.46 (3.12)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,182</sub>&#x000a0;=&#x000a0;1.598</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">Anticholinergic side effects</td><td rowspan="1" colspan="1">9.87 (3.46)</td><td rowspan="1" colspan="1">9.13 (3.66)</td><td rowspan="1" colspan="1">9.92 (3.67)</td><td rowspan="1" colspan="1">9.26 (3.04)</td><td rowspan="1" colspan="1">9.80 (3.86)</td><td rowspan="1" colspan="1">8.33 (2.79)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,185</sub>&#x000a0;=&#x000a0;1.323</td><td rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="1" colspan="1">Other autonomic side effects</td><td rowspan="1" colspan="1">9.27 (3.16)</td><td rowspan="1" colspan="1">8.42 (3.28)</td><td rowspan="1" colspan="1">9.33 (3.69)</td><td rowspan="1" colspan="1">8.95 (2.85)</td><td rowspan="1" colspan="1">9.11 (3.04)</td><td rowspan="1" colspan="1">8.37 (2.50)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,184</sub>&#x000a0;=&#x000a0;0.319</td><td rowspan="1" colspan="1">0.57</td></tr><tr><td rowspan="1" colspan="1">Allergic reactions</td><td rowspan="1" colspan="1">5.57 (1.66)</td><td rowspan="1" colspan="1">5.17 (1.83)</td><td rowspan="1" colspan="1">6.26 (2.49)</td><td rowspan="1" colspan="1">6.58 (2.99)</td><td rowspan="1" colspan="1">6.70 (3.01)</td><td rowspan="1" colspan="1">591 (2.52)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,180</sub>&#x000a0;=&#x000a0;4.839</td><td rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">Psychic side effects</td><td rowspan="1" colspan="1">23.63 (6.34)</td><td rowspan="1" colspan="1">22.36 (7.40)</td><td rowspan="1" colspan="1">24.58 (6.90)</td><td rowspan="1" colspan="1">22.44 (7.42)</td><td rowspan="1" colspan="1">22.75 (7.00)</td><td rowspan="1" colspan="1">22.08 (7.11)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,183</sub>&#x000a0;=&#x000a0;1.295</td><td rowspan="1" colspan="1">0.26</td></tr><tr><td rowspan="1" colspan="1">Hormonal side effects</td><td rowspan="1" colspan="1">8.20 (3.03)</td><td rowspan="1" colspan="1">7.96 (2.22)</td><td rowspan="1" colspan="1">8.33 (2.22)</td><td rowspan="1" colspan="1">8.54 (2.68)</td><td rowspan="1" colspan="1">8.72 (3.12)</td><td rowspan="1" colspan="1">7.38 (2.27)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,178</sub>&#x000a0;=&#x000a0;0.066</td><td rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">Miscellaneous side effects</td><td rowspan="1" colspan="1">6.43 (1.95)</td><td rowspan="1" colspan="1">6.54 (2.19)</td><td rowspan="1" colspan="1">6.96 (1.76)</td><td rowspan="1" colspan="1">6.86 (2.04)</td><td rowspan="1" colspan="1">7.37 (1.80)</td><td rowspan="1" colspan="1">6.83 (2.10)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,184</sub>&#x000a0;=&#x000a0;1.694</td><td rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">Red herrings</td><td rowspan="1" colspan="1">14.52 (4.72)</td><td rowspan="1" colspan="1">14.83 (4.35)</td><td rowspan="1" colspan="1">14.92 (4.49)</td><td rowspan="1" colspan="1">15.14 (4.94)</td><td rowspan="1" colspan="1">15.65 (5.21)</td><td rowspan="1" colspan="1">14.78 (4.73)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,185</sub>&#x000a0;=&#x000a0;0.801</td><td rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">Red herrings &#x02a7e;20</td><td rowspan="1" colspan="1">0.13 (0.35)</td><td rowspan="1" colspan="1">0.17 (0.38)</td><td rowspan="1" colspan="1">0.21 (4.95)</td><td rowspan="1" colspan="1">0.21 (0.41)</td><td rowspan="1" colspan="1">0.20 (0.41)</td><td rowspan="1" colspan="1">0.17 (0.39)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,184</sub>&#x000a0;=&#x000a0;0.446</td><td rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">92.80 (21.061)</td><td rowspan="1" colspan="1">90.9 (23.95)</td><td rowspan="1" colspan="1">95.74 (0.12)</td><td rowspan="1" colspan="1">93.63 (23.27)</td><td rowspan="1" colspan="1">96.00 (27.27)</td><td rowspan="1" colspan="1">87.50 (21.94)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,184</sub>&#x000a0;=&#x000a0;0.041</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">Total without red herring items</td><td rowspan="1" colspan="1">78.41 (17.12)</td><td rowspan="1" colspan="1">75.95 (20.16)</td><td rowspan="1" colspan="1">80.70 (20.47)</td><td rowspan="1" colspan="1">78.69 (19.37)</td><td rowspan="1" colspan="1">80.43 (21.96)</td><td rowspan="1" colspan="1">72.85 (17.66)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,161</sub>&#x000a0;=&#x000a0;0.447</td><td rowspan="1" colspan="1">0.73</td></tr><tr><td rowspan="1" colspan="1">Laboratory measurement</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean clozapine plasma level, ng/ml (<sc>s.d</sc>.)</td><td rowspan="1" colspan="1">421.27 (224.61)</td><td rowspan="1" colspan="1">515.16 (240.43)</td><td rowspan="1" colspan="1">376.48 (185.11)</td><td rowspan="1" colspan="1">461.71 (219.61)</td><td rowspan="1" colspan="1">403.06 (179.90)</td><td rowspan="1" colspan="1">436.14 (157.07)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,178</sub>&#x000a0;=&#x000a0;1.387</td><td rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">Range, ng/ml</td><td rowspan="1" colspan="1">50&#x02013;878</td><td rowspan="1" colspan="1">101&#x02013;1060</td><td rowspan="1" colspan="1">52&#x02013;671</td><td rowspan="1" colspan="1">60&#x02013;1080</td><td rowspan="1" colspan="1">135&#x02013;682</td><td rowspan="1" colspan="1">200&#x02013;715</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Physical examination</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean waist circumference, cm (<sc>s.d</sc>.)</td><td rowspan="1" colspan="1">110.04 (13.82)</td><td rowspan="1" colspan="1">108.32 (14.71)</td><td rowspan="1" colspan="1">104.04 (11.72)</td><td rowspan="1" colspan="1">105.50 (13.89)</td><td rowspan="1" colspan="1">104.41 (12.16)</td><td rowspan="1" colspan="1">107.88 (14.86)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,181</sub>&#x000a0;=&#x000a0;1.205</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">Mean systolic blood pressure, mmHg (<sc>s.d</sc>.)</td><td rowspan="1" colspan="1">134.57 (18.77)</td><td rowspan="1" colspan="1">169.00 (170.28)</td><td rowspan="1" colspan="1">130.26 (12.59)</td><td rowspan="1" colspan="1">130.48 (15.94)</td><td rowspan="1" colspan="1">125.68 (12.82)</td><td rowspan="1" colspan="1">130.75 (11.84)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,188</sub>&#x000a0;=&#x000a0;1.954</td><td rowspan="1" colspan="1">0.16</td></tr><tr><td rowspan="1" colspan="1">Mean diastolic blood pressure, mmHg (<sc>s.d</sc>.)</td><td rowspan="1" colspan="1">88.00 (9.77)</td><td rowspan="1" colspan="1">86.72 (10.57)</td><td rowspan="1" colspan="1">87.04 (8.10)</td><td rowspan="1" colspan="1">85.95 (9.41)</td><td rowspan="1" colspan="1">86.14 (9.70)</td><td rowspan="1" colspan="1">83.88 (7.60)</td><td rowspan="1" colspan="1"><italic>F</italic><sub>1,188</sub>&#x000a0;=&#x000a0;1.084</td><td rowspan="1" colspan="1">0.30</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>AE, Adverse event; LUNSERS, Liverpool University Neuroleptic Side-Effect Rating
Scale; <sc>s.d.,</sc> standard deviation.</p></fn><fn><p><sup>a</sup> Extrapyramidal symptoms: items 19, 29, 34, 37, 40, 43, 48;
anticholinergic side effects: items 6, 10, 32, 38, 51; other autonomic side
effects: items 15, 16, 20, 27, 36; allergic reactions: items 1, 35, 47, 49;
psychic side effects: items 2, 4, 9, 14, 18, 21, 23, 26, 31, 41; hormonal side
effects: items 7, 13, 17, 24, 46, 50; miscellaneous side effects: items 5, 12, 39,
44; red herrings: items 3, 8, 11, 12, 25, 28, 30, 33, 42, 45.</p></fn></table-wrap-foot></table-wrap></p><p>A <italic>post-hoc</italic> analysis showed no evidence to suggest that the six patients
admitted to long-stay wards responded differently to memantine than the 46 out-patients.
In comparison with the full sample of 52 patients, the ESs were nearly identical in
magnitude (data available on request).</p></sec><sec id="sec3-3"><title>Possible confounders</title><p>Tests for period effects and period&#x000a0;&#x000d7;&#x000a0;treatment interaction were non-significant across
all outcomes. When matched-pair <italic>t</italic> tests were used to compare scores from
the first baseline to the second baseline of the trial, carryover effects were significant
for the memory composite from the CANTAB, PANSS positive, negative, and total scores.
<italic>t</italic> Tests and a repeated-measures analysis of variance indicated no
significant differences in clozapine levels across the four assessment times in the trial,
suggesting that memantine has no effect on clozapine levels. Clozapine dosage (mean
350&#x000a0;mg, range&#x000a0;=&#x000a0;75&#x02013;1000&#x000a0;mg) remained unaltered in all subjects except in one subject in
the placebo phase whose clozapine dosage was increased with 175&#x000a0;mg because of agitation
and verbal aggression. Alterations in concomitant medications throughout the study were
limited to changes in benzodiazepines in one subject in the placebo phase. Use of
substances or psychotherapy did not significantly change during the trial (see online
Supplementary Table S3). Tests of moderation based on low and high levels of expectation
for improvement prior to beginning the trial revealed that the element of expectation did
not contribute to the placebo effect. Blinding was successful, in that 45.7% of patients
guessed correctly which group they had been randomized to. The raters were correct in
21.7% of cases.</p></sec><sec id="sec3-4"><title>Safety and tolerability</title><p>No significant changes in liver and renal function were observed. Compared with placebo,
memantine did not significantly affect metabolic parameters, such as waist circumference,
blood pressure, blood glucose or lipids (see <xref ref-type="table" rid="tab03">Table
3</xref>). The only significant increase in reported side effects while taking memantine
was found on the Allergic Reactions subscale of the LUNSERS (rash, sensitivity to sun,
unusual skin marks, and itchy skin).</p><p>Of all AEs (see <xref ref-type="table" rid="tab04">Table 4</xref>), one report of
dizziness, a common side effect of memantine in elderly patients with AD, was probably
related to memantine. Complaints of dizziness were alleviated within 5 days of
discontinuation of study medication. There were two reports of temporary increase in
constipation, which were rated as possibly related to memantine. Both participants had
been already treated with laxatives because of clozapine-induced constipation. We observed
one serious AE (a suicide attempt during the placebo phase). <table-wrap id="tab04" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Adverse events (n)</p></caption><alternatives><graphic xlink:href="S0033291716000398_tab4"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Adverse event</th><th align="left" rowspan="1" colspan="1">Memantine</th><th align="left" rowspan="1" colspan="1">Wash-out phase</th><th align="left" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">No adverse event</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">39</td></tr><tr><td rowspan="1" colspan="1">Dizziness</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Nausea and vomiting</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Flu-like symptoms</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Toxic clozapine plasma level with flu-like symptoms</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Toxic clozapine plasma level without symptoms</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Bronchitis</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Pneumonia and urinary tract infection</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cardiac pain</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Hip pain</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Delirium</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Somnolence</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Increase in auditory hallucinations</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Agitation and verbal aggression</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Admission to a psychiatric unit</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Attempted suicide</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr></tbody></table></alternatives></table-wrap></p></sec></sec><sec id="sec4"><title>Discussion and conclusions</title><p>Inspired by the unique psychopharmacological characteristics of the memantine&#x02013;clozapine
combination and the substantial positive findings of the first proof-of-concept study we
conducted a second proof-of-concept study with a larger sample size and a computerized
cognitive test battery to ensure accurate and objective study data with minimized
inter-rater variability to evaluate the efficacy of memantine as an adjunct to clozapine in
refractory schizophrenia.</p><p>Memantine treatment added to clozapine was associated with significant improvement in
memory (ES&#x000a0;=&#x000a0;0.30). Memory-enhancing effects of the combination therapy of clozapine and
memantine may be a result of up-regulation of synaptic NMDA receptor currents in the
hippocampus, facilitating induction of long-term potentiation and therefore learning and
memory (Kornmeier &#x00026; Sosic-Vasic, <xref rid="ref28" ref-type="bibr">2012</xref>).</p><p>Memantine did not significantly improve executive function (ES&#x000a0;=&#x000a0;0.12). Executive function
is a central cognitive process, involving the PFC, corticocortical and corticosubcortal
networks (Evans <italic>et al.</italic>
<xref rid="ref11" ref-type="bibr">1997</xref>; Lesh <italic>et al.</italic>
<xref rid="ref30" ref-type="bibr">2011</xref>). Enhancement of executive function would
require effects on more elaborate networks and several cognitive domains including planning,
working memory, strategy use, cognitive flexibility and ability to suppress impulsivity.
Apparently, memantine addition does not improve the functioning in these networks, or
alternatively longer treatment duration is needed.</p><p>Negative symptoms significantly improved with a small ES (ES&#x000a0;=&#x000a0;0.29). Memantine affected
diminished expression to a larger extent than social amotivation. Improvement of expressive
deficits may be a result of increased signal transmission with an enhanced signal-to-noise
ratio in the PFC (Geerts &#x00026; Grossberg, <xref rid="ref15" ref-type="bibr">2006</xref>;
Hasan <italic>et al</italic>. <xref rid="ref19" ref-type="bibr">2013</xref>) due to the
particular combination of clozapine and memantine.</p><p>Memantine and placebo did not differ significantly with respect to adverse effects, except
for mild and transient allergic symptoms.</p><p>Improvement of cognitive disturbances and negative symptoms is an important goal for
treatment-resistant schizophrenia. Together these symptoms have a more pronounced impact on
psychosocial functioning and quality of life than positive symptoms (Ventura <italic>et al.</italic>
<xref rid="ref60" ref-type="bibr">2015</xref>). Clinical impairment of memory is one of the
major disabilities in schizophrenia. Specifically, verbal memory is a strong predictor of
functional outcome (Green, <xref rid="ref17" ref-type="bibr">1996</xref>). Favorable effects
of memantine in combination with clozapine may be based on the neuroprotective properties
and pharmacodynamic activities of this combination. In a recent proton magnetic resonance
spectroscopy study anterior cingulate cortex glutamate levels were elevated in patients with
treatment-resistant schizophrenia compared with patients with treatment-responsive
schizophrenia, endorsing our hypothesis that memantine is specifically efficacious in
refractory schizophrenia (Mouchlianitis <italic>et al.</italic>
<xref rid="ref38" ref-type="bibr">2015</xref>).</p><p>The effect of memantine augmentation that we found is in line with the improvement of
negative symptoms that has been found in five trials of addition of a glutamate antagonist
to clozapine in partially responding schizophrenia patients (Goff <italic>et al.</italic>
<xref rid="ref16" ref-type="bibr">2007</xref> (study 926); Zoccali <italic>et al.</italic>
<xref rid="ref65" ref-type="bibr">2007</xref>; Afshar <italic>et al.</italic>
<xref rid="ref1" ref-type="bibr">2008</xref>; de Lucena <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2009</xref>; Muscatello <italic>et al.</italic>
<xref rid="ref40" ref-type="bibr">2010</xref>). Topiramate and lamotrigine both showed
favorable effects on negative symptoms in each of two trials, with ESs varying from 0.76 to
1.37 and 0.66 to 1.21, respectively. Cognitive functioning had been assessed with different
cognitive test batteries in five double-blind, placebo-controlled randomized trials of
clozapine augmentation with glutamate antagonists. In one trial of topiramate (Muscatello
<italic>et al.</italic>
<xref rid="ref40" ref-type="bibr">2010</xref>) and two trials of lamotrigine add-on therapy
to clozapine (Goff <italic>et al.</italic>
<xref rid="ref16" ref-type="bibr">2007</xref> (study 926); Vay&#x00131;so&#x0011f;lu <italic>et al.</italic>
<xref rid="ref56" ref-type="bibr">2013</xref>), cognitive functions did not significantly
change compared with placebo. However, two trials showed favorable results on cognition
(Zoccali <italic>et al.</italic>
<xref rid="ref65" ref-type="bibr">2007</xref>; de Lucena <italic>et al.</italic>
<xref rid="ref9" ref-type="bibr">2009</xref>). In the study by Zoccali <italic>et
al.</italic> (<xref rid="ref65" ref-type="bibr">2007</xref>), the only cognitive function
that significantly improved was semantic fluency after 24 weeks of addition of lamotrigine
200&#x000a0;mg daily.</p><p>The differences and similarities between our results and that of the 12-week memantine
add-on study by de Lucena <italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>) are striking. De Lucena <italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>) found exceptionally large ESs on all treatment outcome parameters.
Most striking was the large ES of 3.33 concerning negative symptoms (de Lucena <italic>et
al.</italic>
<xref rid="ref9" ref-type="bibr">2009</xref>). But also the effect on global cognitive
functioning (ES&#x000a0;=&#x000a0;<italic>&#x02212;</italic>1.32), as measured by the Mini-Mental State Examination
(MMSE) (Folstein <italic>et al.</italic>
<xref rid="ref14" ref-type="bibr">1975</xref>), was substantial. Caution is necessary, for
efficacy of memantine was perhaps overestimated partly by chance in this relatively small
sample study (21 patients) (Sinclair &#x00026; Adams, <xref rid="ref49" ref-type="bibr">2014</xref>; Tajika <italic>et al.</italic>
<xref rid="ref53" ref-type="bibr">2015</xref>). The crossover design of our larger
double-blind randomized clinical trial eliminated the influence of between-subject
variability on effect. The MMSE, used by de Lucena <italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>), does not measure executive functioning and
detects cognitive deficits only at an advanced stage, because tasks for language and memory
functions are extremely simple (Feher <italic>et al.</italic>
<xref rid="ref13" ref-type="bibr">1992</xref>). We used a more sensitive and comprehensive
cognitive test battery developed for assessment of cognitive impairments in schizophrenia
intervention studies (Levaux <italic>et al.</italic>
<xref rid="ref32" ref-type="bibr">2007</xref>). The Brief Psychiatric Rating Scale (BPRS),
used by de Lucena <italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>),
merely covers three negative symptom items (blunted affect, emotional withdrawal and
psychomotor retardation). We used the more sensitive PANSS scale with seven items on the
negative symptom subscale (Eckert <italic>et al.</italic>
<xref rid="ref10" ref-type="bibr">1996</xref>) and four additional items on the general
symptom subscale in the <italic>post-hoc</italic> analysis (Liemburg <italic>et al.</italic>
<xref rid="ref34" ref-type="bibr">2013</xref>). Our patient population differed compared
with that of the first memantine augmentation to clozapine study in mean age (42.35
<italic>v</italic>. 34.67 years) and mean duration of illness (22.88 years
<italic>v</italic>. 17.84 years), CGI-S scores (6.15 <italic>v</italic>. 5.34) and mean
total PANSS and total BPRS scores (81.21 and 14.38, respectively), suggesting that our
patient population was more severely ill than were patients in the study by de Lucena
<italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>). Although in our
patients the severity of residual negative symptoms was comparable with the severity of
persistent positive symptoms (mean PANSS negative subscale&#x000a0;=&#x000a0;22.12, <sc>s.d.</sc>&#x000a0;=&#x000a0;5.86;
mean PANSS positive subscale&#x000a0;=&#x000a0;21.02, <sc>s.d.</sc>&#x000a0;=&#x000a0;6.34), negative symptoms prevailed in
the study by de Lucena <italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>). While mean total BPRS score (14.38) corresponds with &#x02018;markedly ill&#x02019; according
to CGI-S (score 5) in the de Lucena study, our patient population was rated as severely ill
(mean CGI-S score 6.15) due to prominent cognitive impairment. These differences between
studies may partly explain the more moderate beneficial effects of memantine addition in our
study. However, the difference in ES for all symptom domains between the de Lucena study and
ours is very large. It has been demonstrated that among randomized trials, initially
stronger effects are not unusual (Ioannidis, <xref rid="ref23" ref-type="bibr">2005</xref>;
Tajika <italic>et al.</italic>
<xref rid="ref53" ref-type="bibr">2015</xref>). Memantine was generally well tolerated in
both studies. Although there were no drop-outs in the first study, one participant
discontinued in our trial because of dizziness in the memantine phase.</p><p>The results of our study are limited by the short memantine treatment duration of 12 weeks.
A longer treatment duration may result in more pronounced treatment effects associated with
an improved glutamatergic balance, as was found in patients with AD. In a meta-analysis of
six randomized, placebo-controlled trials of memantine treatment in 2311 patients with AD,
symptoms of delusion were more improved after 24 to 28 weeks compared with 12 weeks
(Puangthong &#x00026; Hsiung, <xref rid="ref45" ref-type="bibr">2009</xref>). Furthermore,
the crossover design resulted in carryover effects on several measures, including verbal
memory and all PANSS subscales, despite a 2-week placebo wash-out period. Although the model
controls for carryover effects, these cannot be discarded completely. Practice effects were
minimized due to the fact that the number of subjects randomized to the placebo and
memantine groups before crossover was the same and a parallel form was used for verbal
memory. Tests on executive function, depending on strategy, show strong practice effects and
low test&#x02013;retest reliability (Lowe &#x00026; Rabbitt, <xref rid="ref36" ref-type="bibr">1998</xref>). However, there is no research on practice effects using the CANTAB in
patients with severe cognitive disturbances suffering from refractory schizophrenia.
Although our study included more patients than the first investigation by de Lucena
<italic>et al.</italic> (<xref rid="ref9" ref-type="bibr">2009</xref>) our sample size is
still relatively small (Sinclair &#x00026; Adams, <xref rid="ref49" ref-type="bibr">2014</xref>). The results of our study need to be validated in a randomized multicenter
long-term treatment study with a large sample size and enough power to clearly show a
reduction of at least 25% of the baseline score in order to help further evaluate
pro-cognitive properties of memantine in combination with clozapine in refractory patients
and its potential to reduce negative symptoms associated with schizophrenia (Leucht
<italic>et al.</italic>
<xref rid="ref31" ref-type="bibr">2009</xref>).</p><p>In conclusion, we found evidence that addition of memantine may be a well-tolerated
treatment option for cognitive impairments and negative symptoms in patients with
clozapine-refractory schizophrenia, deserving further study.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the participants of this study and their care providers for their assistance,
enthusiasm and support. We also thank M. Monden and Dr J. B. Deijen for their contribution
to the training of the raters. This research received no specific grant from any funding
agency, commercial or not-for-profit sectors. This work was supported by the Community
Mental Health Division of Mental Health Service Organization North Holland North. The study
was partially funded by the 2012 Care Innovation Prize of Mental Health Service Organization
North Holland North. Both verum and placebo tablets were provided by H. Lundbeck A/S at no
cost. H. Lundbeck A/S did not play any role in the design, conduct, analysis or
interpretation of the trial.</p></ack><fn-group id="fng" content-type="footnotes"><fn id="fns01"><label>&#x02020;</label><p>The notes appear after the main text.</p></fn></fn-group><fn-group content-type="endnotes" id="fng1"><title>Notes</title><fn id="fn1"><label>1</label><p>The full results of the study are available by request from the first author
(S.R.T.V.).</p></fn><fn id="fn2"><label>2</label><p>A period effect was included as a control only as the study does not have sufficient
power to test for such an effect directly. Further, a period effect was not
hypothesized.</p></fn></fn-group><sec sec-type="supplementary-material" id="sec5"><title>Supplementary material</title><supplementary-material content-type="local-data" id="S0033291716000398sup001"><p>For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291716000398.</p><media xlink:href="S0033291716000398sup001.zip" mimetype="application" mime-subtype="zip" orientation="portrait" id="d36e2768" position="anchor"><caption><p>click here to view supplementary material</p></caption></media></supplementary-material></sec><notes notes-type="other" id="nts2"><title>Declaration of Interest</title><p>S.R.T.V. and J.D.S. report no financial relationships with commercial interests. P.F.J.S.
reports personal fees from H. Lundbeck A/S, outside the submitted work and he is a board
member of the Dutch Clozapine Collaboration Group. L.d.H. has received investigator-led
research grants or recompense for presenting his research from Eli Lilly, Bristol-Myers
Squibb, Janssen-Cilag and AstraZeneca.</p></notes><ref-list id="reflist1"><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><name><surname>Afshar</surname><given-names>H</given-names></name>, <name><surname>Roohafza</surname><given-names>H</given-names></name>, <name><surname>Mousavi</surname><given-names>G</given-names></name>, <name><surname>Golchin</surname><given-names>S</given-names></name>, <name><surname>Toghianifar</surname><given-names>N</given-names></name>, <name><surname>Sadeghi</surname><given-names>M</given-names></name>, <name><surname>Talaei</surname><given-names>M</given-names></name> (<year>2008</year>). <article-title>Topiramate add-on treatment in schizophrenia:
a randomised, double blind, placebo controlled clinical trial</article-title>.
<source>Journal of Psychopharmacology</source>
<volume>23</volume>, <fpage>157</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">18515465</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><name><surname>Andreasen</surname><given-names>NC</given-names></name>, <name><surname>Carpenter</surname><given-names>WT</given-names><suffix>Jr.</suffix></name>, <name><surname>Kane</surname><given-names>JM</given-names></name>, <name><surname>Lasser</surname><given-names>RA</given-names></name>, <name><surname>Marder</surname><given-names>SR</given-names></name>, <name><surname>Weinberger</surname><given-names>DR</given-names></name> (<year>2005</year>). <article-title>Remission in schizophrenia: proposed criteria
and rationale for consensus</article-title>. <source>American Journal of Psychiatry</source>
<volume>162</volume>, <fpage>441</fpage>&#x02013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">15741458</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><name><surname>Areosa</surname><given-names>SA</given-names></name>, <name><surname>Sherriff</surname><given-names>F</given-names></name>, <name><surname>McShane</surname><given-names>R</given-names></name> (<year>2005</year>). <article-title>Memantine for dementia</article-title>.
<source>Cochrane Database of Systematic Reviews</source>, Issue 2,
CD003154.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><name><surname>Barnett</surname><given-names>JH</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <name><surname>Leeson</surname><given-names>VC</given-names></name>, <name><surname>Sahakian</surname><given-names>BJ</given-names></name>, <name><surname>Joyce</surname><given-names>EM</given-names></name>, <name><surname>Blackwell</surname><given-names>AD</given-names></name> (<year>2010</year>). <article-title>Assessing cognitive function in clinical
trials of schizophrenia</article-title>. <source>Neuroscience and Biobehavioral Reviews</source>
<volume>34</volume>, <fpage>1161</fpage>&#x02013;<lpage>1177</lpage>.<pub-id pub-id-type="pmid">20105440</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><name><surname>Bliss</surname><given-names>TV</given-names></name>, <name><surname>Collingridge</surname><given-names>GL</given-names></name> (<year>1993</year>). <article-title>A synaptic model of memory: long-term
potentiation in the hippocampus</article-title>. <source>Nature</source>
<volume>361</volume>, <fpage>31</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">8421494</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><name><surname>Bressan</surname><given-names>RA</given-names></name>, <name><surname>Pilowsky</surname><given-names>LS</given-names></name> (<year>2000</year>). <article-title>Imaging the glutamatergic system <italic>in
vivo</italic> &#x02013; relevance to schizophrenia</article-title>. <source>European Journal
of Nuclear Medicine</source>
<volume>27</volume>, <fpage>1723</fpage>&#x02013;<lpage>1731</lpage>.<pub-id pub-id-type="pmid">11105831</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="book"><name><surname>Cohen</surname><given-names>J</given-names></name> (<year>1988</year>). <source>Statistical Power Analysis for the Behavioral
Sciences</source>, <edition>2nd edn.</edition>
<publisher-name>Erlbaum</publisher-name>: <publisher-loc>Hillsdale,
NJ</publisher-loc>.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><name><surname>Day</surname><given-names>JC</given-names></name>, <name><surname>Wood</surname><given-names>G</given-names></name>, <name><surname>Dewey</surname><given-names>M</given-names></name>, <name><surname>Bentall</surname><given-names>RP</given-names></name> (<year>1995</year>). <article-title>A self-rating scale for measuring neuroleptic
side-effects: validation in a group of schizophrenic patients</article-title>.
<source>British Journal of Psychiatry</source>
<volume>166</volume>, <fpage>650</fpage>&#x02013;<lpage>653</lpage>.<pub-id pub-id-type="pmid">7620752</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><name><surname>de Lucena</surname><given-names>D</given-names></name>, <name><surname>Fernandes</surname><given-names>BS</given-names></name>, <name><surname>Berk</surname><given-names>M</given-names></name>, <name><surname>Dodd</surname><given-names>S</given-names></name>, <name><surname>Medeiros</surname><given-names>DW</given-names></name>, <name><surname>Pedrini</surname><given-names>M</given-names></name>, <name><surname>Kunz</surname><given-names>M</given-names></name>, <name><surname>Gomes</surname><given-names>FA</given-names></name>, <name><surname>Giglio</surname><given-names>LF</given-names></name>, <name><surname>Lobato</surname><given-names>MI</given-names></name>, <name><surname>Belmonte-de-Abreu</surname><given-names>PS</given-names></name>, <name><surname>Gama</surname><given-names>CS</given-names></name> (<year>2009</year>). <article-title>Improvement of negative and positive symptoms
in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled
trial with memantine as add-on therapy to clozapine</article-title>. <source>Journal of
Clinical Psychiatry</source>
<volume>70</volume>, <fpage>1416</fpage>&#x02013;<lpage>1423</lpage>.<pub-id pub-id-type="pmid">19906345</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><name><surname>Eckert</surname><given-names>S</given-names></name>, <name><surname>Diamond</surname><given-names>PM</given-names></name>, <name><surname>Miller</surname><given-names>AL</given-names></name>, <name><surname>Velligan</surname><given-names>DI</given-names></name>, <name><surname>Funderburg</surname><given-names>LG</given-names></name>, <name><surname>True</surname><given-names>JF</given-names></name> (<year>1996</year>). <article-title>A comparison of instrument sensitivity to
negative symptom change</article-title>. <source>Psychiatry Research</source>
<volume>63</volume>, <fpage>67</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">8832775</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>JJ</given-names></name>, <name><surname>Chua</surname><given-names>SE</given-names></name>, <name><surname>McKenna</surname><given-names>PJ</given-names></name>, <name><surname>Wilson</surname><given-names>BA</given-names></name> (<year>1997</year>). <article-title>Assessment of the dysexecutive syndrome in
schizophrenia</article-title>. <source>Psychological Medicine</source>
<volume>27</volume>, <fpage>635</fpage>&#x02013;<lpage>646</lpage>.<pub-id pub-id-type="pmid">9153684</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><name><surname>Farlow</surname><given-names>MR</given-names></name>, <name><surname>Graham</surname><given-names>SM</given-names></name>, <name><surname>Alva</surname><given-names>G</given-names></name> (<year>2008</year>). <article-title>Memantine for the treatment of Alzheimer's
disease: tolerability and safety data from clinical trials</article-title>. <source>Drug
Safety</source>
<volume>31</volume>, <fpage>577</fpage>&#x02013;<lpage>585</lpage>.<pub-id pub-id-type="pmid">18558791</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><name><surname>Feher</surname><given-names>EP</given-names></name>, <name><surname>Mahurin</surname><given-names>RK</given-names></name>, <name><surname>Doody</surname><given-names>RS</given-names></name>, <name><surname>Cooke</surname><given-names>N</given-names></name>, <name><surname>Sims</surname><given-names>J</given-names></name>, <name><surname>Pirozzolo</surname><given-names>FJ</given-names></name> (<year>1992</year>). <article-title>Establishing the limits of the Mini-Mental
State: examination of subtests</article-title>. <source>Archives of Neurology</source>
<volume>49</volume>, <fpage>87</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">1728269</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><name><surname>Folstein</surname><given-names>MF</given-names></name>, <name><surname>Folstein</surname><given-names>SE</given-names></name>, <name><surname>McHugh</surname><given-names>PR</given-names></name> (<year>1975</year>). <article-title>&#x02018;Mini-mental state&#x02019;. A practical method for
grading the cognitive state of patients for the clinician</article-title>.
<source>Journal of Psychiatric Research</source>
<volume>12</volume>, <fpage>189</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><name><surname>Geerts</surname><given-names>H</given-names></name>, <name><surname>Grossberg</surname><given-names>GT</given-names></name> (<year>2006</year>). <article-title>Pharmacology of acetylcholinesterase
inhibitors and <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors for combination
therapy in the treatment of Alzheimer's disease</article-title>. <source>Journal of
Clinical Pharmacology</source>
<volume>46</volume>, <fpage>8S</fpage>&#x02013;<lpage>16S</lpage>.<pub-id pub-id-type="pmid">16809810</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><name><surname>Goff</surname><given-names>DC</given-names></name>, <name><surname>Keefe</surname><given-names>R</given-names></name>, <name><surname>Citrome</surname><given-names>L</given-names></name>, <name><surname>Davy</surname><given-names>K</given-names></name>, <name><surname>Krystal</surname><given-names>JH</given-names></name>, <name><surname>Large</surname><given-names>C</given-names></name>, <name><surname>Thompson</surname><given-names>TR</given-names></name>, <name><surname>Volavka</surname><given-names>J</given-names></name>, <name><surname>Webster</surname><given-names>EL</given-names></name> (<year>2007</year>). <article-title>Lamotrigine as add-on therapy in
schizophrenia: results of 2 placebo-controlled trials</article-title>. <source>Journal
of Clinical Psychopharmacology</source>
<volume>27</volume>, <fpage>582</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">18004124</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>MF</given-names></name> (<year>1996</year>). <article-title>What are the functional consequences of
neurocognitive deficits in schizophrenia?</article-title>
<source>American Journal of Psychiatry</source>
<volume>153</volume>, <fpage>321</fpage>&#x02013;<lpage>330</lpage>.<pub-id pub-id-type="pmid">8610818</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="book"><name><surname>Guy</surname><given-names>W</given-names></name> (<year>1976</year>). <chapter-title>Clinical Global Impression
Scale</chapter-title> In <source>ECDEU Assessment Manual for Psychopharmacology</source>,
revised edn. (ed. <string-name>
<given-names>W.</given-names>
<surname>Guy</surname>
</string-name>), pp. <fpage>218</fpage>&#x02013;<lpage>222</lpage>. <publisher-name>US Department
of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research
Branch</publisher-name>: <publisher-loc>Rockville, MD</publisher-loc>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><name><surname>Hasan</surname><given-names>A</given-names></name>, <name><surname>Falkai</surname><given-names>P</given-names></name>, <name><surname>Wobrock</surname><given-names>T</given-names></name> (<year>2013</year>). <article-title>Transcranial brain stimulation in
schizophrenia: targeting cortical excitability, connectivity and
plasticity</article-title>. <source>Current Medicinal Chemistry</source>
<volume>20</volume>, <fpage>405</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">23157633</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><name><surname>Hasan</surname><given-names>A</given-names></name>, <name><surname>Falkai</surname><given-names>P</given-names></name>, <name><surname>Wobrock</surname><given-names>T</given-names></name>, <name><surname>Lieberman</surname><given-names>J</given-names></name>, <name><surname>Glenthoj</surname><given-names>B</given-names></name>, <name><surname>Gattaz</surname><given-names>WF</given-names></name>, <name><surname>Thibaut</surname><given-names>F</given-names></name>, <name><surname>M&#x000f6;ller</surname><given-names>HJ</given-names></name>; <collab>World Federation of Societies of Biological Psychiatry (WFSBP) Task Force
on Treatment Guidelines for Schizophrenia</collab> (<year>2012</year>).
<article-title>World Federation of Societies of Biological Psychiatry (WFSBP) Task Force
on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological
Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update
2012 on the acute treatment of schizophrenia and the management of treatment
resistance</article-title>. <source>World Journal of Biological Psychiatry</source>
<volume>13</volume>, <fpage>318</fpage>&#x02013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">22834451</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><name><surname>Homayoun</surname><given-names>H</given-names></name>, <name><surname>Moghaddam</surname><given-names>B</given-names></name> (<year>2007</year>). <article-title>NMDA receptor hypofunction produces opposite
effects on prefrontal cortex interneurons and pyramidal neurons</article-title>.
<source>Journal of Neuroscience</source>
<volume>27</volume>, <fpage>11496</fpage>&#x02013;<lpage>11500</lpage>.<pub-id pub-id-type="pmid">17959792</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><name><surname>Howes</surname><given-names>OD</given-names></name>, <name><surname>Kapur</surname><given-names>S</given-names></name> (<year>2009</year>). <article-title>The dopamine hypothesis of schizophrenia:
version III &#x02013; final common pathway</article-title>. <source>Schizophrenia Bulletin</source>
<volume>35</volume>, <fpage>549</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">19325164</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><name><surname>Ioannidis</surname><given-names>JP</given-names></name> (<year>2005</year>). <article-title>Contradicted and initially stronger effects in
highly cited clinical research</article-title>. <source>Journal of the American Medical
Associaton</source>
<volume>294</volume>, <fpage>218</fpage>&#x02013;<lpage>228</lpage>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><name><surname>Javitt</surname><given-names>DC</given-names></name>, <name><surname>Zukin</surname><given-names>SR</given-names></name> (<year>1991</year>). <article-title>Recent advances in the phencyclidine model of
schizophrenia</article-title>. <source>American Journal of Psychiatry</source>
<volume>148</volume>, <fpage>1301</fpage>&#x02013;<lpage>1308</lpage>.<pub-id pub-id-type="pmid">1654746</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><name><surname>Joshi</surname><given-names>I</given-names></name>, <name><surname>Yang</surname><given-names>Y-M</given-names></name>, <name><surname>Wang</surname><given-names>L-Y</given-names></name> (<year>2007</year>). <article-title>Cellular/molecular coincident activation of
metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates
perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the
developing calyx of the held synapse</article-title>. <source>Journal of Neuroscience</source>
<volume>27</volume>, <fpage>9989</fpage>&#x02013;<lpage>9999</lpage>.<pub-id pub-id-type="pmid">17855613</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><name><surname>Kantrowitz</surname><given-names>JT</given-names></name>, <name><surname>Javitt</surname><given-names>DC</given-names></name> (<year>2010</year>). <article-title><italic>N</italic>-methyl-<sc>d</sc>-aspartate
(NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to
schizophrenia?</article-title>
<source>Brain Research Bulletin</source>
<volume>83</volume>, <fpage>108</fpage>&#x02013;<lpage>121</lpage>.<pub-id pub-id-type="pmid">20417696</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><name><surname>Kay</surname><given-names>SR</given-names></name>, <name><surname>Fiszbein</surname><given-names>A</given-names></name>, <name><surname>Opler</surname><given-names>LA</given-names></name> (<year>1987</year>). <article-title>The Positive and Negative Syndrome Scale
(PANSS) for schizophrenia</article-title>. <source>Schizophrernia Bulletin</source>
<volume>13</volume>, <fpage>261</fpage>&#x02013;<lpage>276</lpage>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><name><surname>Kornmeier</surname><given-names>J</given-names></name>, <name><surname>Sosic-Vasic</surname><given-names>Z</given-names></name> (<year>2012</year>). <article-title>Parallels between spacing effects during
behavioural and cellular learning</article-title>. <source>Frontiers in Human
Neuroscience</source>
<volume>6</volume>, <fpage>203</fpage>.<pub-id pub-id-type="pmid">22783181</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JG</given-names></name>, <name><surname>Lee</surname><given-names>SW</given-names></name>, <name><surname>Lee</surname><given-names>BJ</given-names></name>, <name><surname>Park</surname><given-names>SW</given-names></name>, <name><surname>Kim</surname><given-names>GM</given-names></name>, <name><surname>Kim</surname><given-names>YH</given-names></name> (<year>2012</year>). <article-title>Adjunctive memantine therapy for cognitive
impairment in chronic schizophrenia: a placebo-controlled pilot study</article-title>.
<source>Psychiatry Investigation</source>
<volume>9</volume>, <fpage>166</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">22707968</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><name><surname>Lesh</surname><given-names>TA</given-names></name>, <name><surname>Niendam</surname><given-names>TA</given-names></name>, <name><surname>Minzenberg</surname><given-names>MJ</given-names></name>, <name><surname>Carter</surname><given-names>CS</given-names></name> (<year>2011</year>). <article-title>Cognitive control deficits in schizophrenia:
mechanisms and meaning</article-title>. <source>Neuropsychopharmacology</source>
<volume>36</volume>, <fpage>316</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">20844478</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><name><surname>Leucht</surname><given-names>S</given-names></name>, <name><surname>Davis</surname><given-names>JM</given-names></name>, <name><surname>Engel</surname><given-names>RR</given-names></name>, <name><surname>Kissling</surname><given-names>W</given-names></name>, <name><surname>Kane</surname><given-names>JM</given-names></name> (<year>2009</year>). <article-title>Definitions of response and remission in
schizophrenia: recommendations for their use and their presentation</article-title>.
<source>Acta Psychiatrica Scandinavica. Supplementum</source>
<volume>438</volume>, <fpage>7</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">19132961</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><name><surname>Levaux</surname><given-names>MN</given-names></name>, <name><surname>Potvin</surname><given-names>S</given-names></name>, <name><surname>Sepehry</surname><given-names>AA</given-names></name>, <name><surname>Sablier</surname><given-names>J</given-names></name>, <name><surname>Mendrek</surname><given-names>A</given-names></name>, <name><surname>Stip</surname><given-names>E</given-names></name> (<year>2007</year>). <article-title>Computerized assessment of cognition in
schizophrenia: promises and pitfalls of CANTAB</article-title>. <source>European
Psychiatry</source>
<volume>22</volume>, <fpage>104</fpage>&#x02013;<lpage>115</lpage>.<pub-id pub-id-type="pmid">17227707</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><name><surname>Lieberman</surname><given-names>JA</given-names></name>, <name><surname>Papadakis</surname><given-names>K</given-names></name>, <name><surname>Csernansky</surname><given-names>J</given-names></name>, <name><surname>Litman</surname><given-names>R</given-names></name>, <name><surname>Volavka</surname><given-names>J</given-names></name>, <name><surname>Jia</surname><given-names>XD</given-names></name>, <name><surname>Gage</surname><given-names>A</given-names></name>; <collab>MEM-MD-29 Study Group</collab> (<year>2009</year>). <article-title>A
randomized, placebo-controlled study of memantine as adjunctive treatment in patients
with schizophrenia</article-title>. <source>Neuropsychopharmacology</source>
<volume>34</volume>, <fpage>1322</fpage>&#x02013;<lpage>1329</lpage>.<pub-id pub-id-type="pmid">19005465</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><name><surname>Liemburg</surname><given-names>E</given-names></name>, <name><surname>Catelein</surname><given-names>S</given-names></name>, <name><surname>Stewart</surname><given-names>R</given-names></name>, <name><surname>van der Gaag</surname><given-names>M</given-names></name>, <name><surname>Aleman</surname><given-names>A</given-names></name>, <name><surname>Knegtering</surname><given-names>H</given-names></name>; <collab>Genetic Risk and Outcome of Psychosis (GROUP) Investigators</collab>
(<year>2013</year>). <article-title>Two subdomains of negative symptoms in psychotic
disorders: established and confirmed in two large cohorts</article-title>.
<source>Journal of Psychiatric Research</source>
<volume>47</volume>, <fpage>718</fpage>&#x02013;<lpage>725</lpage>.<pub-id pub-id-type="pmid">23472837</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="book"><name><surname>Little</surname><given-names>RJA</given-names></name>, <name><surname>Rubin</surname><given-names>DB</given-names></name> (<year>2002</year>). <source>Statistical Analysis with Missing Data</source>,
<edition>2nd edn.</edition>
<publisher-name>John Wiley</publisher-name>: <publisher-loc>New
York</publisher-loc>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><name><surname>Lowe</surname><given-names>C</given-names></name>, <name><surname>Rabbitt</surname><given-names>P</given-names></name> (<year>1998</year>). <article-title>Test/re-test reliability of the CANTAB and
ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge
Neuropsychological Test Automated Battery. International Study of Post-Operative
Cognitive Dysfunction</article-title>. <source>Neuropsychologia</source>
<volume>36</volume>, <fpage>915</fpage>&#x02013;<lpage>923</lpage>.<pub-id pub-id-type="pmid">9740364</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><name><surname>Millan</surname><given-names>MJ</given-names></name>, <name><surname>Fone</surname><given-names>K</given-names></name>, <name><surname>Steckler</surname><given-names>T</given-names></name>, <name><surname>Horan</surname><given-names>WP</given-names></name> (<year>2014</year>). <article-title>Negative symptoms of schizophrenia: clinical
characteristics, pathophysiological substrates, experimental models and prospects for
improved treatment</article-title>. <source>European Neuropsychopharmacology</source>
<volume>24</volume>, <fpage>645</fpage>&#x02013;<lpage>692</lpage>.<pub-id pub-id-type="pmid">24820238</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><name><surname>Mouchlianitis</surname><given-names>E</given-names></name>, <name><surname>Bloomfield</surname><given-names>MA</given-names></name>, <name><surname>Law</surname><given-names>V</given-names></name>, <name><surname>Beck</surname><given-names>K</given-names></name>, <name><surname>Selvaraj</surname><given-names>S</given-names></name>, <name><surname>Rasquinha</surname><given-names>N</given-names></name>, <name><surname>Waldman</surname><given-names>A</given-names></name>, <name><surname>Turkheimer</surname><given-names>FE</given-names></name>, <name><surname>Egerton</surname><given-names>A</given-names></name>, <name><surname>Stone</surname><given-names>J</given-names></name>, <name><surname>Howes</surname><given-names>OD</given-names></name> (<year>2015</year>). <article-title>Treatment-resistant schizophrenia patients
show elevated anterior cingulate cortex glutamate compared to
treatment-responsive</article-title>. <source>Schizophrenia Bulletin</source> pii,
sbv151.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><name><surname>Muscatello</surname><given-names>MR</given-names></name>, <name><surname>Bruno</surname><given-names>A</given-names></name>, <name><surname>De Fazio</surname><given-names>P</given-names></name>, <name><surname>Segura-Garcia</surname><given-names>C</given-names></name>, <name><surname>Pandolfo</surname><given-names>G</given-names></name>, <name><surname>Zoccali</surname><given-names>R</given-names></name> (<year>2014</year>). <article-title>Augmentation strategies in partial responder
and/or treatment-resistant schizophrenia patients treated with
clozapine</article-title>. <source>Expert Opinion on Pharmacotherapy</source>
<volume>15</volume>, <fpage>2329</fpage>&#x02013;<lpage>2345</lpage>.<pub-id pub-id-type="pmid">25284216</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><name><surname>Muscatello</surname><given-names>MR</given-names></name>, <name><surname>Bruno</surname><given-names>A</given-names></name>, <name><surname>Pandolfo</surname><given-names>G</given-names></name>, <name><surname>Mic&#x000f2;</surname><given-names>U</given-names></name>, <name><surname>Bellinghieri</surname><given-names>PM</given-names></name>, <name><surname>Scimeca</surname><given-names>G</given-names></name>, <name><surname>Cacciola</surname><given-names>M</given-names></name>, <name><surname>Campolo</surname><given-names>D</given-names></name>, <name><surname>Settineri</surname><given-names>S</given-names></name>, <name><surname>Zoccali</surname><given-names>R</given-names></name> (<year>2010</year>). <article-title>Topiramate augmentation of clozapine in
schizophrenia: a double-blind, placebo-controlled study</article-title>. <source>Journal
of Psychopharmacology</source>
<volume>25</volume>, <fpage>667</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">20615930</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><name><surname>Nuechterlein</surname><given-names>KH</given-names></name>, <name><surname>Green</surname><given-names>MF</given-names></name>, <name><surname>Kern</surname><given-names>RS</given-names></name>, <name><surname>Baade</surname><given-names>LE</given-names></name>, <name><surname>Barch</surname><given-names>DM</given-names></name>, <name><surname>Cohen</surname><given-names>JD</given-names></name>, <name><surname>Essock</surname><given-names>S</given-names></name>, <name><surname>Fenton</surname><given-names>WS</given-names></name>, <name><surname>Frese</surname><given-names>FJ</given-names><suffix>3rd</suffix></name>, <name><surname>Gold</surname><given-names>JM</given-names></name>, <name><surname>Goldberg</surname><given-names>T</given-names></name>, <name><surname>Heaton</surname><given-names>RK</given-names></name>, <name><surname>Keefe</surname><given-names>RS</given-names></name>, <name><surname>Kraemer</surname><given-names>H</given-names></name>, <name><surname>Mesholam-Gately</surname><given-names>R</given-names></name>, <name><surname>Seidman</surname><given-names>LJ</given-names></name>, <name><surname>Stover</surname><given-names>E</given-names></name>, <name><surname>Weinberger</surname><given-names>DR</given-names></name>, <name><surname>Young</surname><given-names>AS</given-names></name>, <name><surname>Zalcman</surname><given-names>S</given-names></name>, <name><surname>Marder</surname><given-names>SR</given-names></name> (<year>2008</year>). <article-title>The MATRICS consensus cognitive battery, part
1: test selection, reliability and validity</article-title>. <source>American Journal of
Psychiatry</source>
<volume>165</volume>, <fpage>203</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">18172019</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><name><surname>Orellana</surname><given-names>G</given-names></name>, <name><surname>Slachevsky</surname><given-names>A</given-names></name> (<year>2013</year>). <article-title>Executive functioning in
schizophrenia</article-title>. <source>Frontiers in Psychiatry</source>
<volume>4</volume>, <fpage>35</fpage>.<pub-id pub-id-type="pmid">23805107</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="book"><name><surname>Overbeek</surname><given-names>T</given-names></name>, <name><surname>Schruers</surname><given-names>K</given-names></name>, <name><surname>Griez</surname><given-names>E</given-names></name> (<year>1999</year>). <source>MINI. Mini International Neuropsychiatric
Interview</source>. <italic>Dutch version 5.0.0. DSM-IV</italic>
<publisher-name>University of Maastricht</publisher-name>: <publisher-loc>Maastricht,
the Netherlands</publisher-loc>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><name><surname>Parsons</surname><given-names>CG</given-names></name>, <name><surname>Gilling</surname><given-names>K</given-names></name> (<year>2007</year>). <article-title>Memantine as an example of a fast,
voltage-dependent, open channel <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor
blocker</article-title>. <source>Methods of Molecular Biology</source>
<volume>403</volume>, <fpage>15</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><name><surname>Puangthong</surname><given-names>U</given-names></name>, <name><surname>Hsiung</surname><given-names>GY</given-names></name> (<year>2009</year>). <article-title>Critical appraisal of the long-term impact of
memantine in treatment of moderate to severe Alzheimer's disease</article-title>.
<source>Neuropsychiatric Disease and Treatment</source>
<volume>5</volume>, <fpage>553</fpage>&#x02013;<lpage>561</lpage>.<pub-id pub-id-type="pmid">19898670</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><name><surname>Putt</surname><given-names>M</given-names></name>, <name><surname>Chinchilli</surname><given-names>VM</given-names></name> (<year>1999</year>). <article-title>A mixed effects model for the analysis of
repeated measures cross-over studies</article-title>. <source>Statistics in Medicine</source>
<volume>30</volume>, <fpage>3037</fpage>&#x02013;<lpage>3058</lpage>.<pub-id pub-id-type="pmid">10544305</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><name><surname>Rezaei</surname><given-names>F</given-names></name>, <name><surname>Mohammad-Karimi</surname><given-names>M</given-names></name>, <name><surname>Seddighi</surname><given-names>S</given-names></name>, <name><surname>Modabbernia</surname><given-names>A</given-names></name>, <name><surname>Ashrafi</surname><given-names>M</given-names></name>, <name><surname>Salehi</surname><given-names>B</given-names></name>, <name><surname>Hammidi</surname><given-names>S</given-names></name>, <name><surname>Motasami</surname><given-names>H</given-names></name>, <name><surname>Hajiaghaee</surname><given-names>R</given-names></name>, <name><surname>Tabrizi</surname><given-names>M</given-names></name>, <name><surname>Akhondzadeh</surname><given-names>S</given-names></name> (<year>2013</year>). <article-title>Memantine add-on to risperidone for treatment
of negative symptoms in patients with stable schizophrenia: randomized, double-blind,
placebo-controlled study</article-title>. <source>Journal of Clinical Psychopharmacology</source>
<volume>33</volume>, <fpage>336</fpage>&#x02013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">23609382</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><name><surname>Schulte</surname><given-names>PFJ</given-names></name> (<year>2003</year>). <article-title>What is an adequate trial with clozapine?
Therapeutic drug monitoring and time to response in treatment-refractory
schizophrenia</article-title>. <source>Clinical Pharmacokinetics</source>
<volume>42</volume>, <fpage>607</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">12844323</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><name><surname>Sinclair</surname><given-names>D</given-names></name>, <name><surname>Adams</surname><given-names>CE</given-names></name> (<year>2014</year>). <article-title>Treatment resistant schizophrenia: a
comprehensive survey of randomized controlled trials</article-title>. <source>BMC
Psychiatry</source>
<volume>14</volume>, <fpage>253</fpage>.<pub-id pub-id-type="pmid">25227719</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="book"><name><surname>Singer</surname><given-names>JD</given-names></name>, <name><surname>Willett</surname><given-names>JB</given-names></name> (editors) (<year>2003</year>). <source>Applied Longitudinal Data Analysis:
Modeling Change and Event Occurrence</source>. <publisher-name>Oxford University
Press</publisher-name>: <publisher-loc>New York</publisher-loc>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="other"><collab>SPSS Inc.</collab> (<year>2014</year>).
<italic>SPSS Statistics version 22.0.0</italic>. SPSS Inc.: Chicago,
IL.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>JM</given-names></name>, <name><surname>Morrison</surname><given-names>PD</given-names></name>, <name><surname>Pilowsky</surname><given-names>LS</given-names></name> (<year>2007</year>). <article-title>Review: glutamate and dopamine dysregulation
in schizophrenia &#x02013; a synthesis and selective review</article-title>. <source>Journal of
Psychopharmacoly</source>
<volume>21</volume>, <fpage>440</fpage>&#x02013;<lpage>452</lpage>.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><name><surname>Tajika</surname><given-names>A</given-names></name>, <name><surname>Ogawa</surname><given-names>Y</given-names></name>, <name><surname>Takeshima</surname><given-names>N</given-names></name>, <name><surname>Hayasaka</surname><given-names>Y</given-names></name>, <name><surname>Furukawa</surname><given-names>TA</given-names></name> (<year>2015</year>). <article-title>Replication and contradiction of highly cited
research papers in psychiatry: 10-year follow-up</article-title>. <source>British
Journal of Psychiatry</source>
<volume>207</volume>, <fpage>357</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">26159600</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><name><surname>Tanahashi</surname><given-names>S</given-names></name>, <name><surname>Yamamura</surname><given-names>S</given-names></name>, <name><surname>Nakagawa</surname><given-names>M</given-names></name>, <name><surname>Motomura</surname><given-names>E</given-names></name>, <name><surname>Okada</surname><given-names>M</given-names></name> (<year>2012</year>). <article-title>Clozapine, but not haloperidol, enhances glial
<sc>d</sc>-serine and <sc>l</sc>-glutamate release in rat frontal cortex and primary
cultured astrocytes</article-title>. <source>British Journal of Pharmacology</source>
<volume>165</volume>, <fpage>1543</fpage>&#x02013;<lpage>1555</lpage>.<pub-id pub-id-type="pmid">21880034</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><name><surname>van Veldhuizen</surname><given-names>JR</given-names></name> (<year>2007</year>). <article-title>FACT: a Dutch version of ACT</article-title>.
<source>Community Mental Health Journal</source>
<volume>43</volume>, <fpage>421</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">17514502</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><name><surname>Vay&#x00131;so&#x0011f;lu</surname><given-names>S</given-names></name>, <name><surname>An&#x00131;l Ya&#x0011f;c&#x00131;o&#x0011f;lu</surname><given-names>AE</given-names></name>, <name><surname>Ya&#x0011f;c&#x00131;o&#x0011f;lu</surname><given-names>S</given-names></name>, <name><surname>Karahan</surname><given-names>S</given-names></name>, <name><surname>Karc&#x00131;</surname><given-names>O</given-names></name>, <name><surname>G&#x000fc;rel</surname><given-names>SC</given-names></name>, <name><surname>Yaz&#x00131;c&#x00131;</surname><given-names>MK</given-names></name> (<year>2013</year>). <article-title>Lamotrigine augmentation in patients with
schizophrenia who show partial response to clozapine treatment</article-title>.
<source>Schizophrenia Research</source>
<volume>143</volume>, <fpage>207</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">23217729</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><name><surname>Veerman</surname><given-names>SRT</given-names></name>, <name><surname>Schulte</surname><given-names>PF</given-names></name>, <name><surname>Begemann</surname><given-names>MJ</given-names></name>, <name><surname>de Haan</surname><given-names>L</given-names></name> (<year>2014</year><italic>a</italic>). <article-title>Non-glutamatergic clozapine
augmentation strategies: a review and meta-analysis</article-title>.
<source>Pharmacopsychiatry</source>
<volume>47</volume>, <fpage>231</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">25121994</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><name><surname>Veerman</surname><given-names>SRT</given-names></name>, <name><surname>Schulte</surname><given-names>PF</given-names></name>, <name><surname>Begemann</surname><given-names>MJ</given-names></name>, <name><surname>Engelsbel</surname><given-names>F</given-names></name>, <name><surname>de Haan</surname><given-names>L</given-names></name> (<year>2014</year><italic>b</italic>). <article-title>Clozapine augmented with
glutamate modulators in refractory schizophrenia: a review and
metaanalysis</article-title>. <source>Pharmacopsychiatry</source>
<volume>47</volume>, <fpage>185</fpage>&#x02013;<lpage>194</lpage>.<pub-id pub-id-type="pmid">25002291</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><name><surname>Veerman</surname><given-names>SRT</given-names></name>, <name><surname>Schulte</surname><given-names>PF</given-names></name>, <name><surname>de Haan</surname><given-names>L</given-names></name> (<year>2014</year><italic>c</italic>). <article-title>The glutamate hypothesis: a
pathogenic pathway from which pharmacological interventions have
emerged</article-title>. <source>Pharmacopsychiatry</source>
<volume>47</volume>, <fpage>121</fpage>&#x02013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">25002292</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><name><surname>Ventura</surname><given-names>J</given-names></name>, <name><surname>Subotnik</surname><given-names>KL</given-names></name>, <name><surname>Gitlin</surname><given-names>MJ</given-names></name>, <name><surname>Gretchen-Doorly</surname><given-names>D</given-names></name>, <name><surname>Ered</surname><given-names>A</given-names></name>, <name><surname>Villa</surname><given-names>KF</given-names></name>, <name><surname>Hellemann</surname><given-names>GS</given-names></name>, <name><surname>Nuechterlein</surname><given-names>KH</given-names></name> (<year>2015</year>). <article-title>Negative symptoms and functioning during the
first year after a recent onset of schizophrenia and 8 years later</article-title>.
<source>Schizophrenia Research</source>
<volume>161</volume>, <fpage>407</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">25499044</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><name><surname>Wesemann</surname><given-names>W</given-names></name>, <name><surname>Sontag</surname><given-names>KH</given-names></name>, <name><surname>Maj</surname><given-names>J</given-names></name> (<year>1983</year>). <article-title>Pharmacodynamics and pharmacokinetics of
memantine</article-title>. <source>Arzniemittelforschung</source>
<volume>33</volume>, <fpage>1122</fpage>&#x02013;<lpage>1134</lpage>.</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><name><surname>Winblad</surname><given-names>B</given-names></name>, <name><surname>Jones</surname><given-names>RW</given-names></name>, <name><surname>Wirth</surname><given-names>Y</given-names></name>, <name><surname>St&#x000f6;ffler</surname><given-names>A</given-names></name>, <name><surname>M&#x000f6;bius</surname><given-names>HJ</given-names></name> (<year>2007</year>). <article-title>Memantine in moderate to severe Alzheimer's
disease: a meta-analysis of randomised clinical trials</article-title>. <source>Dementia
and Geriatric Cognitive Disorders</source>
<volume>24</volume>, <fpage>20</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">17496417</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><collab>World Medical Association</collab>
(<year>2013</year>). <article-title>World Medical Association Declaration of Helsinki:
ethical principles for medical research involving human subjects</article-title>.
<source>Journal of the American Medical Association</source>
<volume>310</volume>, <fpage>2191</fpage>&#x02013;<lpage>2194</lpage>.<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><name><surname>Yeun</surname><given-names>EY</given-names></name>, <name><surname>Zhong</surname><given-names>P</given-names></name>, <name><surname>Yan</surname><given-names>Z</given-names></name> (<year>2010</year>). <article-title>Homeostatic regulation of glutamatergic
transmission by dopamine D4 receptors</article-title>. <source>Proceedings of the
National Academy of Sciences USA</source>
<volume>107</volume>, <fpage>22308</fpage>&#x02013;<lpage>22313</lpage>.</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><name><surname>Zoccali</surname><given-names>R</given-names></name>, <name><surname>Muscatello</surname><given-names>MR</given-names></name>, <name><surname>Bruno</surname><given-names>A</given-names></name>, <name><surname>Cambria</surname><given-names>R</given-names></name>, <name><surname>Mic&#x000f2;</surname><given-names>U</given-names></name>, <name><surname>Spina</surname><given-names>E</given-names></name>, <name><surname>Meduri</surname><given-names>M</given-names></name> (<year>2007</year>). <article-title>The effect of lamotrigine augmentation of
clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind,
placebo-controlled study</article-title>. <source>Schizophrenia Research</source>
<volume>93</volume>, <fpage>109</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">17383857</pub-id></mixed-citation></ref></ref-list></back></article>